PURPOSE: To determine whether massively parallel next-generation DNA sequencing offers rapid and efficient detection of disease-causing mutations in patients with monogenic inherited diseases. Retinitis pigmentosa (RP) is a challenging application for this technology because it is a monogenic disease in individuals and families but is highly heterogeneous in patient populations. RP has multiple patterns of inheritance, with mutations in many genes for each inheritance pattern and numerous, distinct, disease-causing mutations at each locus; further, many RP genes have not been identified yet. METHODS: Next-generation sequencing was used to identify mutations in pairs of affected individuals from 21 families with autosomal dominant RP, selected from a cohort of families without mutations in "common" RP genes. One thousand amplicons targeting 249,267 unique bases of 46 candidate genes were sequenced with the 454GS FLX Titanium (Roche Diagnostics, Indianapolis, IN) and GAIIx (Illumina/Solexa, San Diego, CA) platforms. RESULTS: An average sequence depth of 70× and 125× was obtained for the 454GS FLX and GAIIx platforms, respectively. More than 9000 sequence variants were identified and analyzed, to assess the likelihood of pathogenicity. One hundred twelve of these were selected as likely candidates and tested for segregation with traditional di-deoxy capillary electrophoresis sequencing of additional family members and control subjects. Five disease-causing mutations (24%) were identified in the 21 families. CONCLUSION: This project demonstrates that next-generation sequencing is an effective approach for detecting novel, rare mutations causing heterogeneous monogenic disorders such as RP. With the addition of this technology, disease-causing mutations can now be identified in 65% of autosomal dominant RP cases.
PURPOSE: To determine whether massively parallel next-generation DNA sequencing offers rapid and efficient detection of disease-causing mutations in patients with monogenic inherited diseases. Retinitis pigmentosa (RP) is a challenging application for this technology because it is a monogenic disease in individuals and families but is highly heterogeneous in patient populations. RP has multiple patterns of inheritance, with mutations in many genes for each inheritance pattern and numerous, distinct, disease-causing mutations at each locus; further, many RP genes have not been identified yet. METHODS: Next-generation sequencing was used to identify mutations in pairs of affected individuals from 21 families with autosomal dominant RP, selected from a cohort of families without mutations in "common" RP genes. One thousand amplicons targeting 249,267 unique bases of 46 candidate genes were sequenced with the 454GS FLX Titanium (Roche Diagnostics, Indianapolis, IN) and GAIIx (Illumina/Solexa, San Diego, CA) platforms. RESULTS: An average sequence depth of 70× and 125× was obtained for the 454GS FLX and GAIIx platforms, respectively. More than 9000 sequence variants were identified and analyzed, to assess the likelihood of pathogenicity. One hundred twelve of these were selected as likely candidates and tested for segregation with traditional di-deoxy capillary electrophoresis sequencing of additional family members and control subjects. Five disease-causing mutations (24%) were identified in the 21 families. CONCLUSION: This project demonstrates that next-generation sequencing is an effective approach for detecting novel, rare mutations causing heterogeneous monogenic disorders such as RP. With the addition of this technology, disease-causing mutations can now be identified in 65% of autosomal dominant RP cases.
Authors: Lori S Sullivan; Sara J Bowne; David G Birch; Dianna Hughbanks-Wheaton; John R Heckenlively; Richard Alan Lewis; Charles A Garcia; Richard S Ruiz; Susan H Blanton; Hope Northrup; Anisa I Gire; Robyn Seaman; Hatice Duzkale; Catherine J Spellicy; Jingya Zhu; Suma P Shankar; Stephen P Daiger Journal: Invest Ophthalmol Vis Sci Date: 2006-07 Impact factor: 4.799
Authors: M Hayakawa; K Fujiki; A Kanai; M Matsumura; Y Honda; H Sakaue; M Tamai; T Sakuma; T Tokoro; T Yura; N Kubota; S Kawano; M Matsui; M Yuzawa; Y Oguchi; K Akeo; E Adachi; T Kimura; Y Miyake; M Horiguchi; K Wakabayashi; N Ishizaka; K Koizumi; M Uyama; N Ohba Journal: Jpn J Ophthalmol Date: 1997 Jan-Feb Impact factor: 2.447
Authors: Sara J Bowne; Lori S Sullivan; Sarah E Mortimer; Lizbeth Hedstrom; Jingya Zhu; Catherine J Spellicy; Anisa I Gire; Dianna Hughbanks-Wheaton; David G Birch; Richard A Lewis; John R Heckenlively; Stephen P Daiger Journal: Invest Ophthalmol Vis Sci Date: 2006-01 Impact factor: 4.799
Authors: Yuko Wada; Michael A Sandberg; Terri L McGee; Melissa A Stillberger; Eliot L Berson; Thaddeus P Dryja Journal: Invest Ophthalmol Vis Sci Date: 2005-05 Impact factor: 4.799
Authors: Chen Zhao; Deepti L Bellur; Shasha Lu; Feng Zhao; Michael A Grassi; Sara J Bowne; Lori S Sullivan; Stephen P Daiger; Li Jia Chen; Chi Pui Pang; Kanxing Zhao; Jonathan P Staley; Catharina Larsson Journal: Am J Hum Genet Date: 2009-10-29 Impact factor: 11.025
Authors: C Ziviello; F Simonelli; F Testa; M Anastasi; S B Marzoli; B Falsini; D Ghiglione; C Macaluso; M P Manitto; C Garrè; A Ciccodicola; E Rinaldi; S Banfi Journal: J Med Genet Date: 2005-07 Impact factor: 6.318
Authors: Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop Journal: Hum Mol Genet Date: 2015-04-15 Impact factor: 6.150
Authors: Sara J Bowne; Marian M Humphries; Lori S Sullivan; Paul F Kenna; Lawrence C S Tam; Anna S Kiang; Matthew Campbell; George M Weinstock; Daniel C Koboldt; Li Ding; Robert S Fulton; Erica J Sodergren; Denis Allman; Sophia Millington-Ward; Arpad Palfi; Alex McKee; Susan H Blanton; Susan Slifer; Ioanna Konidari; G Jane Farrar; Stephen P Daiger; Peter Humphries Journal: Eur J Hum Genet Date: 2011-06-08 Impact factor: 4.246
Authors: Lori S Sullivan; Sara J Bowne; Melissa J Reeves; Delphine Blain; Kerry Goetz; Vida Ndifor; Sally Vitez; Xinjing Wang; Santa J Tumminia; Stephen P Daiger Journal: Invest Ophthalmol Vis Sci Date: 2013-09-19 Impact factor: 4.799
Authors: Stephen P Daiger; Sara J Bowne; Lori S Sullivan; Kari Branham; Dianna K Wheaton; Kaylie D Jones; Cheryl E Avery; Elizabeth D Cadena; John R Heckenlively; David G Birch Journal: Adv Exp Med Biol Date: 2018 Impact factor: 2.622
Authors: Jennifer D Churchill; Sara J Bowne; Lori S Sullivan; Richard Alan Lewis; Dianna K Wheaton; David G Birch; Kari E Branham; John R Heckenlively; Stephen P Daiger Journal: Invest Ophthalmol Vis Sci Date: 2013-02-19 Impact factor: 4.799